Literature DB >> 28289435

Erratum to: Agonist Opioid Treatment as historical comprehensive treatment ('Dole & Nyswander' methodology) is associated with better toxicology outcome than Harm Reduction Treatment.

Jacopo V Bizzarri1, Valentina Casetti1, Livia Sanna1, Angelo Giovanni Icro Maremmani2,3, Luca Rovai2, Silvia Bacciardi2, Daria Piacentino1, Andreas Conca1, Icro Maremmani2,3,4.   

Abstract

[This corrects the article DOI: 10.1186/s12991-016-0109-z.].

Year:  2017        PMID: 28289435      PMCID: PMC5304387          DOI: 10.1186/s12991-017-0132-8

Source DB:  PubMed          Journal:  Ann Gen Psychiatry        ISSN: 1744-859X            Impact factor:   3.455


Erratum to: Ann Gen Psychiatry (2016) 15:34 DOI 10.1186/s12991-016-0109-z

After publication of our article [1], we realised that the title used was incorrect. The correct title “Agonist Opioid Treatment as historical comprehensive treatment (‘Dole and Nyswander’ methodology) is associated with better toxicology outcome than Harm Reduction Treatment” appears above. In addition, it has come to our attention that we did not declare a potential competing interest which is that Molteni Pharmaceutical agreed to provide funds to cover the article-processing charge before we submitted our article to Annals of General Psychiatry.
  1 in total

1.  The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment.

Authors:  Jacopo V Bizzarri; Valentina Casetti; Livia Sanna; Angelo Giovanni Icro Maremmani; Luca Rovai; Silvia Bacciardi; Daria Piacentino; Andreas Conca; Icro Maremmani
Journal:  Ann Gen Psychiatry       Date:  2016-11-25       Impact factor: 3.455

  1 in total
  1 in total

Review 1.  Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health.

Authors:  Barbara Lovrecic; Mercedes Lovrecic; Branko Gabrovec; Marco Carli; Matteo Pacini; Angelo G I Maremmani; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2019-01-09       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.